The IL-12 cytokine family, consisting of the heterodimers IL-12, -23, -27, and -35, has received increased attention because of its diverse and complex functions in immunity. IL-12 consists of a p40 and a p35 subunit
1 and stimulates the differentiation and activation of naive CD4
+ T cells toward a T
H1 phenotype, promoting IFN-γ production.
2 The role of IL-12 in disease has been confounded by the discovery of IL-23, which consists of the same p40 subunit coupled to a unique p19 subunit.
3 IL-23 promotes both the proliferation of effector/memory T
H1 cells and the maintenance of T
H17 cells whose signature cytokine is IL-17.
4 Interestingly, homodimerization of p40 yields a unique molecule capable of anti-inflammatory function through blockade of the IL-12Rβ1
5,6 but also of proinflammatory function as a chemoattractant for dendritic cells and macrophages.
7,8 Muddying the waters further, p35 can also interact with a second binding partner, Epstein-Barr virus–induced gene-3 (EBI3), forming the inhibitory cytokine IL-35.
9,10 IL-35 promotes the proliferation of and IL-10 production by CD4
+CD25
+ FoxP3
+ natural Tregs, inhibits the proliferation of CD4
+CD25
− effector cells, and inhibits the differentiation of T
H17 cells. Thus, IL-35 is considered an anti-inflammatory cytokine. The final current member of the family, IL-27, consists of EBI3 and p28 (IL-30) and enhances T
H1 polarization of naive CD4 T cells.
11